Keloid
Conditions
Interventions
Keloid tissue sample group:None
Normal skin tissue sample group:None
Sponsors
Shenzhen People's Hospital, The First Affiliated Hospital of Southern University of Science and Technology and The Second Clinical Medical College of Jinan University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1.Inclusion criteria for scar tissue samples: (1) Age 18-60 years old (including 18 and 60 years old), male or female; (2) Patients diagnosed as keloid according to the diagnostic criteria of China Plastic Surgery: scar growth exceeds the original damage range and invades the surrounding normal skin, and there is no infection at the focus; (3) Scar course>12 months and no obvious softening, regression trend; (4) Clinical samples are kept intact; (5) exclusion of patients who can tolerate surgery; 2.Inclusion criteria for normal skin tissue samples in the control group: (1) Age ranging from 18 to 60 years old (inclusive), gender not restricted; (2) Excess normal skin tissue removed due to other plastic and aesthetic surgeries (such as double eyelid surgery, facial wrinkle reduction surgery, flap transfer surgery, etc.); (3) Patients who are not keloid patients; (4) Patients who do not have contraindications for surgery and can tolerate the surgery.
Exclusion criteria
Exclusion criteria: 1.Exclusion criteria for scar tissue samples: (1) Patients with keloid who have received other treatments such as drugs, laser and radiotherapy before surgery; (2) Pregnant or lactating women; (3) Patients complicated with malignant tumors, immune disorders and blood system diseases; (4) Complicated with other skin diseases that can affect the results of this study; (5) Patients with surgical contraindications who cannot tolerate surgery. 2.Exclusion criteria for normal skin tissue samples in the control group: (1) Patients have old scars at the surgical site. (2) Patients' scars on other non-surgical areas have a duration of less than 12 months and are still in the proliferative stage. (3) Patients have other skin diseases that may affect the results of this study. (4) Pregnant or lactating women; those with malignant tumors, immune dysfunction, and blood system diseases; (5) Patients considered by the researchers to be unsuitable for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Biological markers DLX5 and HOXB2; | — |
Countries
China
Contacts
Public ContactWei Zhe
Shenzhen People's Hospital, The First Affiliated Hospital of Southern University of Science and Technology and The Second Clinical Medical College of Jinan University
Outcome results
None listed